CTOs on the Move

Ribometrix

www.ribometrix.com

 
Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Ribometrix raised $30M on 11/13/2018

Similar Companies

CareDx

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.

zacharon

zacharon is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cambrian Biopharma

We partner with exceptional scientists to bring a new class of medicines to patients in need, built around understanding the deep science of the “Nine Hallmarks of Aging” with the potential to both treat and prevent today`s deadliest diseases.

Whitmyer Biomechanix

Whitmyer Biomechanix is a Tallahassee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fore Biotherapeutics

As a leader in precision oncology, Fore Biotherapeutics provides patients with unaddressed cancer mutations new hope by connecting them with hyper-targeted medicines. Fore`s integrated functional genomics and machine learning capabilities, known as Foresight, are elucidating disease biology in competitively distinct and unparalleled ways that allow us to uniquely identify clinical-stage assets for people with few to no therapeutic alternatives. Fore is advancing its lead program, FORE8394, to treat both V600 and non-V600 BRAF mutations and continues to refine its clinical approach to serve more patient populations with difficult-to-treat mutations across oncogenes.